Literature DB >> 10429209

Structural and kinetic analysis of drug resistant mutants of HIV-1 protease.

B Mahalingam1, J M Louis, C C Reed, J M Adomat, J Krouse, Y F Wang, R W Harrison, I T Weber.   

Abstract

Mutants of HIV-1 protease that are commonly selected on exposure to different drugs, V82S, G48V, N88D and L90M, showed reduced catalytic activity compared to the wild-type protease on cleavage site peptides, CA-p2, p6pol-PR and PR-RT, critical for viral maturation. Mutant V82S is the least active (2-20% of wild-type protease), mutants N88D, R8Q, and L90M exhibit activities ranging from 20 to 40% and G48V from 50 to 80% of the wild-type activity. In contrast, D30N is variable in its activity on different substrates (10-110% of wild-type), with the PR-RT site being the most affected. Mutants K45I and M46L, usually selected in combination with other mutations, showed activities that are similar to (60-110%) or greater than (110-530%) wild-type, respectively. No direct relationship was observed between catalytic activity, inhibition, and structural stability. The mutants D30N and V82S were similar to wild-type protease in their stability toward urea denaturation, while R8Q, G48V, and L90M showed 1.5 to 2.7-fold decreased stability, and N88D and K45I showed 1.6 to 1.7-fold increased stability. The crystal structures of R8Q, K45I and L90M mutants complexed with a CA-p2 analog inhibitor were determined at 2.0, 1.55 and 1.88 A resolution, respectively, and compared to the wild-type structure. The intersubunit hydrophobic contacts observed in the crystal structures are in good agreement with the relative structural stability of the mutant proteases. All these results suggest that viral resistance does not arise by a single mechanism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10429209     DOI: 10.1046/j.1432-1327.1999.00514.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  52 in total

1.  Optimized labeling of 13CHD2 methyl isotopomers in perdeuterated proteins: potential advantages for 13C relaxation studies of methyl dynamics of larger proteins.

Authors:  R Ishima; J M Louis; D A Torchia
Journal:  J Biomol NMR       Date:  2001-10       Impact factor: 2.835

2.  A comparative study of HIV-1 and HTLV-I protease structure and dynamics reveals a conserved residue interaction network.

Authors:  Pia Rücker; Anselm H C Horn; Heike Meiselbach; Heinrich Sticht
Journal:  J Mol Model       Date:  2011-01-29       Impact factor: 1.810

3.  HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements.

Authors:  Johnson Agniswamy; Chen-Hsiang Shen; Annie Aniana; Jane M Sayer; John M Louis; Irene T Weber
Journal:  Biochemistry       Date:  2012-03-20       Impact factor: 3.162

4.  Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ring.

Authors:  Yu-Chung E Chang; XiaXia Yu; Ying Zhang; Yunfeng Tie; Yuan-Fang Wang; Sofiya Yashchuk; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Med Chem       Date:  2012-03-22       Impact factor: 7.446

5.  Prediction of methyl-side chain dynamics in proteins.

Authors:  Dengming Ming; Rafael Brüschweiler
Journal:  J Biomol NMR       Date:  2004-07       Impact factor: 2.835

6.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

7.  Drug resistance in HIV-1 protease: Flexibility-assisted mechanism of compensatory mutations.

Authors:  Stefano Piana; Paolo Carloni; Ursula Rothlisberger
Journal:  Protein Sci       Date:  2002-10       Impact factor: 6.725

8.  Identifying binding hot spots on protein surfaces by mixed-solvent molecular dynamics: HIV-1 protease as a test case.

Authors:  Peter M U Ung; Phani Ghanakota; Sarah E Graham; Katrina W Lexa; Heather A Carlson
Journal:  Biopolymers       Date:  2016-01       Impact factor: 2.505

9.  Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly.

Authors:  Wolfgang Resch; Rainer Ziermann; Neil Parkin; Andrea Gamarnik; Ronald Swanstrom
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Functional correlates of insertion mutations in the protease gene of human immunodeficiency virus type 1 isolates from patients.

Authors:  E Y Kim; M A Winters; R M Kagan; T C Merigan
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.